Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148323 · ClinicalTrials.gov registry record
HemoSphere Alta Study
A clinical trial of Hemodynamic Instability, sponsored by Edwards Lifesciences.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07148323: Recruiting study of Hemodynamic Instability, sponsored by Edwards Lifesciences.
NCT07148323 is a study of Hemodynamic Instability that is actively recruiting participants, run by Edwards Lifesciences. The registered enrollment target is 100 participants, below the 6,285-participant average among 5 other Hemodynamic Instability trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07148323, a study of Hemodynamic Instability, is actively recruiting participants, sponsored by Edwards Lifesciences.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, non-randomized single arm study using the HemoSphere Alta Advanced Monitoring Platform and associated devices in adult subjects. Data collected from enrolled study subjects will be used for continual device development purposes.
Primary Outcome
Number of patients who receive monitoring using the HemoSphere Alta Advanced Monitoring Platform and associated devices for continued device development.
Conditions Studied
Interventions
- DEVICE HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2026-12 |
What NCT07148323 shows while recruiting
NCT07148323 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 6,285-participant average among 5 other Hemodynamic Instability trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hemodynamic Instability appearing as the primary indexed condition, and to 1 intervention - of which HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor is the first listed.
NCT07148323 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07148323 about?
NCT07148323 is a clinical study titled "HemoSphere Alta Study". A prospective, non-randomized single arm study using the HemoSphere Alta Advanced Monitoring Platform and associated devices in adult subjects. Data collected from enrolled study subjects will be used for continual device development purposes.
What is the current status of trial NCT07148323?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-10-14. Estimated completion is 2026-12.
What conditions does trial NCT07148323 study?
This clinical trial studies the following conditions: Hemodynamic Instability.
What interventions are being tested in trial NCT07148323?
The interventions under investigation include: HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor (DEVICE).
Who is sponsoring clinical trial NCT07148323?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148323 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemodynamic Instability
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Resuscitative TEE Collaborative Registry
RECRUITING
-
Hemodynamics Monitoring During Lower Body Negative Pressure (LBNP) Induced Controlled Hypovolemia
RECRUITING
-
Consortium for Optimized Integration of Bio-Artificial Blood Components for Adaptive Resuscitation Therapy
RECRUITING
-
A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning
ACTIVE NOT RECRUITING · NA
-
Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus.
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI